BLACK WEEKSViale −15 % · kompleti −10 % · ostalo −5 %s kodoBrezplačna dostava v Nemčiji od 200 €

Ta stran je bila prevedena samodejno in lahko vsebuje napake. Ste materni govorec? Veseli bomo vaših povratnih informacij in popravkov.Pošljite povratne informacije

The Peptide Desk The Peptide Desk
Mazdutide, fotografija izdelka
GLP-1

Mazdutide

GLP-1

  • Odprema iz Nemčije

Naročilo

Cena na kos - Brezplačna dostava v Nemčiji od 200 € med Black Weeks
  • DHL s sledenjem
  • Diskretna embalaža

4.6 od 5 na Trustpilotu73 ocen

Iskano tudi kot: Mazdutid · LY3305677 · IBI362

Na prvi pogled

Mazdutide v številkah

Ključni podatki iz našega leksikona.

Celoten vnos v leksikonu
Class
GLP-1 / glucagon dual agonistoxyntomodulin analogue
Half-life
Several daysweekly dose
Frequency
Once weeklysubcutaneous
Form
Lyophilised powderreconstituted with BAC water
Sizes
5 to 10 mg2 sizes in the shop

Znanje

Vse o Mazdutide

Priporočljivo zraven

Kaj potrebujete zraven

Bakteriostatska voda se samodejno doda v vašo košarico. Brizge in robčki z enim klikom.

Inzulinske brizge

10 kos. · 5.50 €

Alkoholni robčki

50 kos. · 10 €

Koliko vode?

Enote na brizgi za vašo velikost viale.

Odpri kalkulator →

FAQ

Pogosta vprašanja

Viri za vsak odgovor: vnos v leksikonu

Imate še vprašanje?

Pišite nam, naša ekipa vam bo pomagala.

Is Mazdutide approved?

In China, yes. The first approval came in June 2025 for long-term weight management in obesity or overweight with a related condition, type 2 diabetes followed in September 2025. Mazdutide is not approved in the EU or the USA, ChEMBL lists phase 3 as the highest phase. The information here describes the state of research and is not a recommendation for use.

How does Mazdutide differ from Tirzepatide and Retatrutide?

The receptors. Mazdutide acts on GLP-1 and glucagon, Tirzepatide on GLP-1 and GIP, Retatrutide on all three. Mazdutide is derived from the gut hormone oxyntomodulin, which naturally addresses both receptors. A running trial with a higher dose compares it directly with Tirzepatide, there are no results yet.

What did the phase 3 trials show?

In GLORY-1 weight fell by 11.0 and 14.0 percent on average after 48 weeks, on placebo it rose by 0.3 percent. In GLORY-2 with a higher dose it was 16.7 versus 1.5 percent after 60 weeks. In type 2 diabetes HbA1c fell by 1.57 and 2.15 percentage points after 24 weeks (placebo 0.14). Against dulaglutide both doses were ahead for HbA1c and weight.

How long does Mazdutide stay in the body?

In the first phase 1b study in China the half-life was between 6.3 and 16.8 days. An attached fatty acid makes this possible. That fits one dose a week, which is how all trials give Mazdutide.

How high were the doses in trials?

The highest study dose was 16 mg per week, in a phase 1 study and a phase 2 trial in the USA. There weight fell by 18.1 percent after 32 weeks, but 20 percent stopped because of side effects. All trials raise the dose in steps over weeks. The entry describes the same principle: start low and only increase while there is no noticeable effect. This is not a dosing recommendation.

Which side effects were seen?

Mainly gastrointestinal effects, mostly mild to moderate. In GLORY-2 53.1 percent had vomiting, 46.9 percent nausea and 39.4 percent diarrhoea (placebo 1.3, 3.2 and 6.5 percent). In GLORY-1 only 0.5 to 1.5 percent stopped because of side effects. In an early study the complaints occurred mainly in the first dose levels.

Which trials are still running?

Four of the listed phase 3 trials are not finished yet: on fatty liver versus semaglutide, on sleep apnoea, in adolescents and on high blood pressure. Phase 2 trials are running on heart failure with obesity and on fatty liver with inflammation (MASH).

Sorodno

Sorodni izdelki